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Abstract  
Prediction of local exposure following inhalation of a locally acting pulmonary drug is central to the 
successful development of novel inhaled medicines, as well as generic equivalents.  This work 
provides a comprehensive review of the state of the art with respect to multiscale computer models 
designed to provide a mechanistic prediction of local and systemic drug exposure following 
inhalation. The availability and quality of underpinning in vivo and in vitro data informing the 
computer based models is also considered.  
Mechanistic modelling of local exposure has the potential to speed up and improve  the chances of  
successful inhaled  API and product development. Although there are examples  in the literature 
where this type of modelling has been used to understand and explain local and systemic exposure, 
there are two main barriers to more widespread use.  There is a lack of generally recognized 
commercially available computational models that incorporate mechanistic modelling of regional 
lung particle deposition and drug disposition processes to simulate  free tissue drug concentration.  
There is also a need for physiologically relevant, good quality experimental data to inform such 
modelling. For example, there are no standardized experimental methods to characterize the 
dissolution of solid drug in the lungs or measure airway permeability.   
Hence, the successful application of mechanistic computer models to understand local exposure 
after inhalation and support product development and regulatory applications hinges on: (i) 
establishing reliable, bio-relevant means to acquire experimental data, and (ii) developing  proven 
mechanistic computer models that combine: a mechanistic model of aerosol deposition and post-
deposition processes in  physiologically-based pharmacokinetic models that predict free local tissue 
concentrations. 
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Graphical abstract  
 
  
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Keywords 
Drug Delivery, Aerosol, Deposition, Dissolution, Permeation, Respiratory, PBPK 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
1. Lung exposure to inhaled drugs  
Successful development of inhaled medicines for the treatment of lung diseases such as asthma and 
chronic obstructive pulmonary disease (COPD) requires an understanding of local exposure and local 
target interactions (Cooper et al, 2012). Historically, the development of a novel inhalation drug 
relied on a series of preclinical and early clinical tests of increasing complexity to progress candidate 
drugs or terminate those that, for example, were not potent enough, had an unsuitable 
pharmacokinetic profile or did not possess  a significant therapeutic window (i.e. exhibited toxicity at 
therapeutic doses (Forbes et al, 2011). These experimental methods are necessary to establish the  
safety and efficacy of a novel medicine. However, they do not necessarily provide a mechanistic 
understanding of how the drug delivery system, the formulation and the drug molecule interact with 
lung physiology to provide an optimal balance between the extent and duration of therapeutic effect 
and unwanted systemic side effects. Hence, relying solely on experimental methods may result in 
extended development programs and high attrition rates, especially for drugs with novel therapeutic 
targets. To avoid this, empirical results can be combined with multiscale computer models to 
provide a mechanistic prediction of drug exposure in target organs (Eissing et al, 2011). 
As an example of multiscale computer models, physiological based pharmacokinetic (PBPK) models 
predict the exposure of drug in a target organ based on absorption, distribution, metabolism and 
elimination (ADME) in that organ, if such information is available (Zhuang and Lu, 2016). PBPK 
models of some type are used by most pharmaceutical companies to guide the molecular design of 
inhaled drugs. However, the combination of PBPK models, which provide understanding of tissue 
and target interactions, with mechanistic models, which describe key processes governing the rate 
and extent of local drug exposure, is still in its infancy. For example, there is currently only one 
commercially available PBPK software with a mechanistic regional deposition, dissolution and 
permeation model designed for pulmonary drug delivery (GastroplusTM Nasal-Pulmonary 
Compartmental Absorption and Transit Model, SimulationsPlus Inc., Rochester, US). Other 
commercial PBPK software, such as the SimCyp SimulatorTM account for pulmonary delivery by 
reducing dissolution and epithelial permeation into a single first order process in a single pulmonary 
compartment (https://www.certara.com/software/physiologically-based-pharmacokinetic-
modeling-and-simulation/simcyp-simulator/absorption/).  
Unlike empirical population-based modelling, which can be used to analyse and interpret the clinical 
pharmacokinetics of inhaled drugs (Borghard et al 2016a; Borghardt et al 2016b; Bartels et al 2013), 
mechanistic modelling requires identification of each key step leading up to and controlling rate and 
extent of absorptive clearance, as well as an understanding of the local and systemic tissue 
interactions (Borghardt et al 2015). These mechanism-based models are deterministic, but semi 
empirical in that they rely on robust quantitative data characterizing each of these key processes 
(Korzekwa et al, 2017). Thus, the development of good experimental model is a mandatory first step  
for producing the data that informs the mechanistic lung retention/clearance model that underpin 
any holistic PBPK model that describes these processes and their interactions to predict lung 
exposure to drugs after inhalation. 
This article will review current understanding of key processes governing local pulmonary exposure 
and our ability to characterise these experimentally as well as the potential of commercial and 
published computer based mechanistic models to reliably predict local pulmonary exposure after 
inhaled drug delivery. Potential for further model development, including gaps in supporting in vitro, 
ex vivo and in vivo data to inform the modelling, will be identified. In section 2 of this article, each of 
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these key processes is considered critically with respect to influence on pulmonary exposure to drug 
and the nature of data generated. Key experimental (input) data required to inform the 
computational models is classified into factors determining aerosol deposition (Table 1) and 
processes that affect the fate of drug after particle deposition (Table 2). We then describe 
commercial and published computer based mechanistic models for predicting local and systemic 
exposure after inhaled drug delivery and consider their pros and cons and potential future 
developments to improve robustness and quality (Section 3) before reviewing knowledge gaps that 
may be clinically important and identifying research priorities to address these uncertainties and the 
limits they impose on current mechanistic models (Section 4). 
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2. Experimental systems/data for use in modelling exposure after inhalation 
The processes that are generally recognised as key determinants of free drug concentration in 
pulmonary tissue are aerosol deposition, particle dissolution, non-absorptive clearance from lung, 
absorptive clearance from lung and drug-tissue interactions (Niven 2014; Olsson et al 2011).  Each of 
these processes are considered below.  
 
2.1. Aerosol Deposition  
The extent and pattern of drug deposition following inhalation of an aerosolized drug is a function of 
the total emitted dose, aerodynamic particle size distribution (APSD), patient inhalation manoeuvre, 
aerosol linear velocity profile and drug bolus profile, as well as airway physiology (se e.g. Delvadia et 
al, 2016). As an obvious critical product attribute, aerosol quality is the focus of much of 
experimental product characterization. Aspects such as delivered dose and the APSD are studied 
using standardized filter methods (USP <603>) and impactor type methods (USP <601>) or laser 
diffraction methods (USP <429>), respectively. The actual clinical impact of aerosol characterization 
data is less straightforward. Delivered (or emitted) dose can be regarded as the body burden dose 
and is important as both a quality attribute and as an indicator of product safety. However, for a 
locally-acting inhaled medicine, a measure reflecting lung deposited dose or lung deposition pattern 
may be more predictive of therapeutic performance (Hastedt et al, 2016, Olsson et al, 2013, 
Bäckman et al, 2017).  
The most common measure of lung dose is Fine Particle Mass (FPM), either as the calculated mass of 
the drug aerosol below a fixed aerodynamic size cut-off (e.g. < 5 µm), or as an actual impactor stage 
grouping.  There are some issues with using FPM as a general measure of lung dose. For example, at 
high velocities and/or large aerodynamic particle sizes, the standard USP throat model generally 
underestimates the real throat losses and hence over estimates lung dose (Zhou et al, 2011). 
Instead, several methods based on assessing mouth-throat (MT) deposition using physiological 
throat models have been proposed.  These methods are generally based on determining aerosol 
filtration through a patient derived upper airway geometry during a patient-realistic inhalation 
manoeuvre. Examples include: the OPC throats (Burnell et al, 2007); the VCU throat models 
(Delvadia et al 2012); and the idealized Alberta throat (DeHaan and Finlay, 2001). Encouragingly, 
these models generally provide a good prediction of clinical MT deposition suggesting that these 
methods indeed provide a good empirical model of initial lung deposited dose. For instance, Zhou et 
al, (2011) and Olsson et al (2013) reported a good correlation between the clinically observed lung 
dose and the Alberta and OPC throat cast filtration, respectively. Similarly, Longest et al. (2016) 
reported a very good correlation between computational fluid dynamics (CFD) predictions and 
experimental deposition data for the VCU model.  These throat models can be also used in 
combination with particle sizing methods, to learn more about the particle size of the aerosol 
fraction which has passed the throat model (Wei et al 2014). The latter may be important for 
assessment of lung deposition pattern, as will be discussed below. 
CFD models have been proposed as an alternative to physical models for assessing MT deposition, 
especially as they can predict the deposition within an actual patient geometry (De Backer et al, 
2015). CFD based models generally require information with respect to the linear airflow velocity as 
it leaves the mouthpiece (in addition to the aerodynamic particle size and patient inhalation profile), 
which makes this approach a bit more complex than a direct measure. However, there are published 
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data showing excellent correlation between CFD predicted deposition patterns in MT region and the 
trachea and corresponding experimental measures (cf. Longest et al, 2016) suggesting that the 
method is robust in its prediction of MT deposition and perhaps deposition in the first few large 
airway generations.  
Unfortunately, neither physical models, nor current state of CFD technology, allow for predictions of 
deposition pattern beyond the first few generations of the large airways. This lack of methodology to 
characterize the distribution of the aerosol within the lung is a significant limitation preventing a full 
understanding of how changes to a product, or patient disease state, may influence clinical 
performance.  As examples where intra pulmonary deposition patterns may influence clinical 
performance, bronchodilator activity is suggested to be driven mainly by the central airway dose 
(Usmani et al, 2005), whereas inhaled corticosteroids may be more effective when targeted to the 
bronchiolar region (Dekhuijzen, 2012). Variations in deposition pattern may also influence 
pulmonary bioavailability and hence systemic exposure and potential side effects (see e.g. Brutche 
et al, 2001, Bäckman and Olsson, 2016, Bäckman et al, 2017).  
Efforts to quantify aerosol deposition patterns in the lower airways are today based on 1-
dimensonal typical path models (see. e.g. Schum and Yeh, 1980), alone or in combination with 
physiological MT models or complex CFD based models to improve predictability of the MT 
deposition. Examples of 1-dimensional models are the ARLA online calculator from Alberta 
University (Finlay and Martin 2008), the MPPD software from ARA (Anjivel et al 1995) and the 
commercially available Mimetikos PreludiumTM (Mimetikos/Emmace AB, Lund, Sweden, 
http://www.emmace.se/mimetikos-preludium/). All three models enable the user to predict 
regional deposition in a Weibel type lung model (Weibel, 1963) based on the APSD and the 
inhalation flow profile (cf. Table 1). As an example, the PreludiumTM model is informed directly by 
impactor data (APSD), obscuration profiles (drug release) and experimental inhalation profiles.  
In summary, experimental techniques to characterize aerosols are well established and so are the 
computer based models converting the aerosol data into a prediction of drug deposition. However, 
the deposition models all lack direct clinical validation beyond the first few generations of the large 
conducting airways since available imaging methods (e.g. gamma scintigraphy) lack the required 
resolution. This obviously limits full evaluation of deposition model robustness (see also discussion in 
section 4 and Table 3). Nevertheless, successful development and application of any PBPK model to 
predict local exposure is likely to require at least an assessment of lung dose, and optimally an 
assessment of deposition pattern, i.e. distribution of drug in the lungs. 
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Table 1.  In vitro and in silico techniques for quantitative evaluation of the drug aerosol deposition following 
inhalation.   
Parameter 
Clinical Impact Technique Status Supportive data Comment 
Emitted or 
delivered dose 
Total body 
burden dose 
In vitro filter 
measurement and/or 
total impactor sized mass 
Well established. 
Pharmacopeial 
monograph methods for 
all product types. 
None May be dependent 
on airflow rate 
Total lung 
dose 
Efficacious dose 
Systemic 
exposure 
Cascade impactor fine 
particle mass 
Well established. 
Pharmacopeial 
monograph methods for 
some product types 
Expected patient 
inhalation flow 
May only reflect lung 
dose in some cases 
Physiological mouth-
throat model 
Emerging as a clinically 
relevant in vitro test 
method 
Patient inhalation flow 
profile  
Limited clinical 
validation, optimal 
use in combination 
with breath simulator 
Computational fluid 
dynamics model 
Emerging as a clinically 
relevant in silico method  
Aerodynamic particle 
size distribution, linear 
velocity profile, patient 
geometry, drug bolus 
Validated against in 
vitro measures 
Lung 
deposition 
pattern 
Efficacious dose 
Systemic 
exposure 
1-dimensional deposition 
models 
Well established 
computational methods 
 
Total dose, patient 
inhalation flow profile, 
lung/airway geometry, 
mouth-throat dose, 
aerodynamic particle 
size distribution, drug 
bolus 
No validation but a 
requirement for a 
successful 
mechanistic model 
 
2.2. Drug release (dissolution) and solubility  
Clinical data on compounds with low water solubility suggest a strong relationship between mean 
absorption time (MAT) from lung and water solubility (Forbes et al, 2015). That would point towards 
in situ dissolution being a critical attribute, i.e. a potential rate limiting step for systemic absorption 
and thus a determinant of pulmonary exposure. Recent work by Bäckman et al (2017) and Melin et 
al (2017) also indicated a key role for dissolution in regulating rate of absorption into the systemic 
circulation for poorly soluble drugs. Given the potential clinical importance, a significant amount of 
work has been undertaken to develop in vitro dissolution tests, ranging from standard USP type test 
setups to more complex in vivo mimicking designs (May et al 2014, Gerde et al, 2017).  State of the 
art regarding dissolution testing of inhaled products has been reviewed in a separate article in this 
issue (Rossi et al, 2017.).  For quality control and regulatory purposes, the most important aspect of 
dissolution methods is that they should be discriminatory and provide reliable, robust data (Forbes 
et al, 2015).  Since the pioneering work on dissolution methods for inhaled products at the beginning 
of the century (Davis and Faddah, 2003; Son et al, 2009; reviewed by Riley et al 2012), many 
experimental variations including some offered as commercial services have evolved and data is 
being included in regulatory submissions, although to date methods have not been adopted by any 
pharmacopoeia. 
If they are to inform mechanistic modelling, dissolution assays must be predictive of the in vivo 
processes, thus an important consideration is whether the heterogeneity of the lung can be 
represented in a single assay.  There are also challenges of how to introduce relevant doses of 
appropriate aerosol fractions to the dissolution vessel and the selection of biorelevant medium in 
terms of composition and volume.  At a recent workshop to discuss a proposed inhaled 
biopharmaceutical classification system (iBCS), dissolution was considered to be of greater 
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importance than solubility (Hastedt et al 2016) – although the two are clearly linked.  For 
pharmacokinetic modelling and simulation to understand the fate of drugs deposited in the lungs, 
estimations of lung solubility and dissolution rates in biorelevant media are required.  This includes 
the modelling of any changes to solubility and dissolution that occur in disease conditions (Wang et 
al 2014). 
Drug solubility in the lungs has been measured in a variety of fluids, including (in order of 
physiological relevance) in vitro measurements in water or physiological salt solutions, often 
supplemented with phospholipids or a surfactant such as sodium dodecyl sulphate, and dilutions of 
products based on lung surfactant extracts such as Survanta® or Curosurf®.  Inhaled particles deposit 
in a thin film of 12-25 mL of lung lining fluid spread over an area of 100 m2 (Frohlich et al 2016). The 
composition of lung lining fluid is complex but mainly consists of lipids and proteins. The majority of 
lipid portion is composed of phosphatidylcholines (PC) among which 1, 2 dipalmitoyl PC represent 
about 40-60%. Other lipids included 1-palmitoyl-2-myristoylPC, 1-palmitoyl-2-oleylPC, 
phosphatidylglycerols and neutral lipids such as cholesterol. Lung surfactants contain specific 
proteins termed as surfactant proteins: SP-A, SP-B, SP-C and SP-D.  The lipids present in the lung 
surfactant can self-assemble to form various structures.  For mechanistic modelling purposes, inputs 
for drug solubility in the lungs have included solubility in PBS (Jones and Harrison, 2012, Bäckman et 
al, 2017) and fasted simulated intestinal fluid (Boger et al, 2016).  Liquid crystalline nanostructures in 
lung surfactant have recently been suggested to have potential effect on respiratory drug delivery, 
by serving as drug depots thus increasing the residence time of the drug in the lungs and providing a 
lung retentive mechanism (Das and Stewart, 2016).  Investigation of such mechanisms and inclusion 
of such interactions in mechanistic modelling will help in better prediction of pulmonary exposure to 
inhaled drugs.   
In summary, significant data is accumulating pointing towards dissolution as a key critical product 
property for inhaled drugs with low water solubility. Several in vitro dissolution models have been 
developed of varied complexity and shown to discriminate between compound or product 
dissolution in a manner consistent with solubility and particle surface area. Hence, the use of 
dissolution test methods to understand variability in dissolution within a product, or between an 
originator product and a generic equivalent, appears to be useful and feasible. However, method 
robustness and clinical impact of observed changes in dissolution profiles require further attention, 
especially if method standardization is to be achieved to underpin regulatory use or inclusion into an 
iBCS. The latter will also require consensus as to selection of dissolution media for use in such 
assays. For prediction of clinical impact of the rate of absorption from the respiratory tract, it is 
possible given the complexity of the human lung that the best use of an in vitro dissolution method 
is not as a stand-alone predictive measure of dissolution in vivo, but rather as key data informing 
mechanistic computer based absorption models. Here, the impact of compound dissolution may be 
addressed in the context of other kinetically competing processes, i.e. absorptive and non-
absorptive clearance as discussed below.  
 
2.3. Non-absorptive clearance 
Mucociliary clearance (MCC) can be approximated as a first order process (O’Riordan et al, 1992) 
with capability to remove a significant proportion of the delivered dose of poorly water soluble drug 
particles from the lungs (Brutche et al, 2001, Bäckman et al, 2017), thus potentially reducing local 
bioavailability.  The same would be expected to apply to highly mucus bound drugs.  MCC may be 
assayed in vitro or ex vivo by measuring particle transport by cell cultures or explants, or by 
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measuring ciliary beat frequency as an index of MCC velocity (Donnelley et al 2017).  Mucociliary 
transport rates have also been studied in vivo in animals and human volunteers (Donnelley et al, 
2014a, Bondesson et al, 2007)). It is recognised that clearance velocity is altered by some inhaled 
drugs and may be reduced in disease (Donnelley et al, 2014b) and may also vary between species 
(Hoffman and Asgharian, 2003). A variety of methods for studying drug binding to mucus and 
particle diffusion in models of respiratory mucus have been developed and this is currently an active 
area of research (Giorgetti 2016; Griessinger et al 2015 ). Unfortunately, most available methods can 
only evaluate total MCC from lung (Bondesson et al, 2007), hence regional variation in MCC is not 
well understood, especially when considering its potential impact on drug residence time in deep 
lung. Accelerated mucus clearance by cough is beyond the scope of current mechanistic models. 
Alveolar macrophages (AM) protect the lung surface against the inhaled pathogens or dust particles. 
Lombry et al, (2004) demonstrated the important role played by respiratory macrophages in the 
disposition of inhaled macromolecules by depleting AM in rats which produced a sevenfold 
enhancement in pulmonary absorption of IgG and human chorionic gonadotropin after intratracheal 
instillation. Alveolar macrophages have also been investigated as targets for anti-inflammatory 
inhaled drugs, capitalizing on their propensity for sequestration of particles. For instance, Axelsson 
et al (2002) demonstrated AM targeting and prolonged anti-inflammatory effect following 
administration of a liposomal steroid prodrug. However, AM capture is not generally believed to 
have a significant impact on the overall rate of absorption of small inhaled drug molecules. 
Metabolism contributes to non-absorptive clearance from the lungs and the nature and extent of 
metabolic activity in freshly isolated human lung parenchymal cells has been reported (Somers et al, 
2007).  As most measurements are performed in lung homogenates, there are uncertainties 
regarding regional variation in the lungs and drug access to enzymes in sub-cellular compartments.  
Species differences, metabolic enzyme polymorphism and expression of different isoforms within a 
range of ontogeny, populations and disease may also be important factors to consider. Some 
activities such as esterification of inhaled steroidal drugs are well-known examples of pulmonary 
metabolism (Miller-Larsson et al, 1998). In an interesting modelling approach for lung metabolism, 
Campbell et al. (2015) developed a regional PBPK model for lung for 1,3-butadiene and its 
metabolites taking into account metabolic capabilities specific to sub-divided regions within lungs 
such as oral/nasal pathways, conducting airways (trachea, bronchi, and anterior bronchioles), 
transitional airways (terminal bronchioles), and the alveolar region. Results showed that inclusion of 
differential lung metabolism was important for explaining the observed species differences in the 
pulmonary metabolism of 1,3-butadiene. 
In conclusion, MCC is the predominant non-absorptive clearance process for poorly soluble small 
molecules inhaled as powders. AM clearance and local metabolism is likely to influence rate and 
extent of pulmonary absorption only for specific types of API, e.g. macromolecules and prodrugs.  
Unfortunately, MCC and its variation in rate in different regions of the airway and in disease is not 
well understood which limits the robustness of any mechanistic model predictions where this 
mechanism plays a significant role regulating pulmonary bioavailability and local residence time. 
 
2.4. Absorptive clearance 
Absorptive clearance removes locally-acting inhaled drugs from their site of action in the lungs.  The 
rate and extent of absorption of inhaled drugs will depend on the relative rates of competing 
clearance mechanisms that operate in the lungs.  Clearance by absorptive transfer from the lung 
lumen is predominately controlled by the epithelial permeability of free (unbound) drug.  In vitro 
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epithelial cell culture (Forbes and Ehrhart, 2005) and ex vivo lung methods (Tronde et al, 2008) are 
available to screen the permeability of inhaled drugs, and may be configured to avoid or account for 
the impact of non-absorptive clearance.  For example, the summing of BDP & 17-BMP during 
permeation in cell layers (Grainger et al, 2012) and the contribution of mucociliary clearance has 
been deconvoluted from absorptive clearance in the isolated perfused lungs (IPL) (Pang et al, 2005). 
Methods have been optimized for culturing the most popular respiratory human respiratory 
epithelial cell lines, 16HBE14o- cells (Ehrhardt et al, 2002 Forbes et al 2003), Calu-3 cells (Grainger et 
al 2006), such that they exhibit epithelial barrier-like properties to permit the permeability of 
compounds to be measured.  Primary human bronchial epithelial cells have been used, but are less 
convenient.  Despite efforts to develop new human cell lines, only primary epithelial cell cultures 
produce suitable monolayers to model the alveolar epithelial permeability barrier to drug 
absorption. There are several methodological variations in IPL which are configured to measure 
clearance from the airways (Tronde et al, 2008), and the dependency of the absorptive clearance 
rate on the method for delivering drugs and maintaining the lungs ex vivo requires more research.  
Apparent permeability coefficients measured in airway cell lines (Mathias et al 2002, Manford et al 
2005) and absorption rate in IPL have been explored to predict absorption in vivo based on 
physicochemical molecular descriptors (Tronde et al, 2003a, 2003b, Edwards et al, 2016).   
Absorption rate is governed by molecular properties such as lipophilicity, ionization state and target 
affinity. Several models have attempted to systematize this, for example the QSAR model developed 
by Cooper et al (2010) to predict efficacious doses of inhaled compounds based on lung plasma 
partitioning. The QSAR model recently reported by Edwards et al (2016) identified key molecular 
drivers for pulmonary absorption using a relatively large set of 82 discovery compounds along with 
17 marketed compounds which were evaluated for absorptive clearance in IPL. Nine compounds 
were further evaluated to test the model’s predictive ability. Molecular descriptors associated with 
permeability and hydrophobicity were found to be positively correlated with pulmonary absorption 
whereas descriptors for charge, ionization and size were negatively correlated. Such QSAR modelling 
exercises can generate descriptors which can be used as inputs during the mechanistic inhalation 
modelling during the drug discovery phase where limited experimental data is available.  For 
example, computational, multiscale, cell-based modelling has been used to explore the relationship 
between the physicochemical properties and absorptive pharmacokinetics of monobasic molecules 
in the lungs (Yu et al 2010).   
A programme to assess the effect of permeability on lung concentration after pulmonary 
administration is generating an expanding and consistent dataset for antibiotic compounds 
absorption from rat lungs in vivo (Gontijo et al, 2014a, Gontijo et al, 2014b, Marchand et al, 2015, 
Marchand et al, 2016). In these experiments a standardized protocol was used with compound 
administration using the Penn Century system and drug concentration determined simultaneously in 
plasma and epithelial lung fluid (ELF) of healthy rats at various times following intravenous (IV) and 
pulmonary administration. Plasma and ELF concentrations produced by both routes of 
administration were used in compartmental analysis and a population PK approach to estimate 
exposure (AUC) in plasma and ELF.  Lung concentrations after pulmonary delivery were highly 
dependent on epithelial permeability, with major therapeutic advantage in lung exposure for 
antibiotics with low permeability precluding oral administration. These in vivo results correlate 
relatively well with in vitro data using Calu-3 cells and physico-chemical characteristics such as Log D 
values, suggesting a place for permeability in an iBCS. Interestingly in vivo data obtained with 
moxifloxacin suggested a P-gp mediated efflux transport (Gontijo et al, 2014a).   
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In general, the impact of transporters has mostly been investigated in vitro and ex vivo as reviewed 
recently (Ehrhardt et al, 2017), but active transport mechanisms have yet to be modelled 
mechanistically to explore their impact on the pharmacokinetics of inhaled drugs.  Expression 
patterns of transporters differs drastically across cell populations in the lungs, including transporters 
belonging to the family of the solute carriers (SLC) such as OCT, OAT, OATP and PEPT and the ATP-
binding cassette (ABC) transporters such as Pgp, MRP and BCRP Nickel et al. (2016).  The big 
question – if and to what extent pulmonary transporters alter the pharmacokinetics of inhaled drugs 
- still needs to be clarified. In a notable clinical study, Ruparelia et al (2008) administered the Pgp 
substrate 99mTc-sestamibi as an aerosol to healthy smokers, non-smokers and COPD patients 
recorded clearance from the lungs scintigraphically for 30 min. The results indicated upregulation of 
Pgp activity in healthy smokers leading to delayed elimination of administered drug, whereas 
elimination was not altered in COPD patients and healthy non-smokers. However, there are few 
quantitative studies demonstrating altered inhaled drug disposition by transporters in humans to 
validate in vitro and ex vivo experimental findings and justify incorporation into PBPK models. 
To summarize, absorptive clearance of free dissolved drug in ELF is controlled by epithelial 
permeability. For hydrophilic compounds, experimental evidence suggests epithelial permeability as 
the rate-limiting step controlling the rate of system absorption, whereas for lipophilic compounds 
the rate of dissolution is more influential. Several methods have been developed to assess drug 
permeability, including QSAR methods based on drug physicochemical properties, in vitro cell assays 
and ex-vivo methods such as the rat IPL model. These methods provide predictions of the 
quantitative absorptive clearance from the lung and hence a good predictor of systemic exposure. 
However, there is a significant increase in epithelial thickness, and a massive reduction in surface 
area in the alveolar interstitial region compared to the conducting airways. This would suggest that 
the bulk of systemically absorbed drug is derived from the alveolar interstitial area, thus 
measurements in IPL and in vivo models may not reflect the rate and mechanisms of absorptive 
clearance from the conducting airway regions and local concentrations in this region (Ehrhardt et al, 
2017). Conducting airway tissue are regarded as the main therapeutic target for bronchodilators and 
inhaled corticosteroids (Usmani et al, 2005 and Dekhuijzen, 2012, respectively). Hence, neither the 
impact of regional variation passive permeability or the influence of active transport on clinical 
efficacy are completely understood.    
 
2.5. Tissue retention and lung concentration 
Many strategies for the design of lung-retained inhaled API have been based on mechanisms that 
lower free drug concentrations and reduce absorptive and metabolic clearance.  This reduction in 
free drug may be conferred by ‘tissue affinity’, which includes collectively sequestration in lung lining 
fluid or tissue compartments though specific and non-specific protein binding, vesicular, lysosomal 
or cytoplasmic trapping.  These mechanisms may provide a depot-effect, thereby retaining drug in 
the lungs.  Non-specific binding is typically low affinity and high capacity; interactions from which 
dissociation rates are generally rapid and do not favour a “slow release” depot.  In contrast, some 
drugs may be retained in the lung through high affinity receptor binding (Collingwood et al 2012).  
For dibasic drugs including the -agonists pH-dependent lysosomal trapping is a mechanism that can 
retain drug in the lungs (Ufuk et al, 2017; Bäckström et al, 2016b).  Poorly water soluble drugs may 
be retained in structures in lung lining fluid (Das and Stewart, 2016), and may be influenced by drug 
formulation.  Binding to respiratory mucus may also be a retentive mechanism if MCC is slow, e.g. in 
disease states, or where mucus is the target, e.g. for antibiotic therapy.  While drug uptake into 
macrophages may represent a first step towards non-absorptive clearance by removal from the 
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lungs or degradation, it may also provide a depot from which drug may be released (Axelsson et al, 
2002). 
Lung tissue binding is typically measured by equilibrium dialysis or ultrafiltration methods (Cooper et 
al 2010), and can be measured by direct assessment of partitioning between lung tissue slices and 
buffer (Bäckström et al, 2016a). Isolated perfused lung models may also be used to establish tissue 
plasma partitioning coefficients when operated in recirculation mode (Tronde at al, 2003b). Non-
lung tissues and lung homogenates are commonly to study non-specific protein binding.  When using 
lung homogenates, tissue affinity is often assessed in comparison with plasma binding which largely 
reflects drug binding to albumin (which is also present in the lung lining fluid albeit in lower 
concentrations).  Tissue-binding or more specific retention mechanisms must be included in PBPK 
models if they are to reflect these important mechanisms of drug retention in the lungs. 
Unbound drug concentration in the lungs provides the most relevant measure for target 
engagement and activity (Cooper et al, 2012), but measurement is problematic.  Microdialysis is 
probably the most elegant technique for on-line determination of unbound drug concentrations in 
tissue interstitial fluid (ISF) both in animals and human (Marchand et al, 2016). However, it presents 
several limitations. Compounds with high molecular weight may not diffuse through the membranes 
and those with high lipophilicity may bind to the probe and tubing components precluding 
microdialysis studies. Furthermore in vivo probe recovery must be determined individually which 
adds complexity and may considerably extend study duration to such a point that it may become 
problematic for animal experiments or not compatible with patients-care for human studies. And 
lung microdialysis is the most challenging since it must be conducted under open chest surgery and 
therefore general anaesthesia which may also interfere with drug tissue distribution. Therefore 
although lung microdialysis studies have occasionally been conducted, in particular in rats 
(Marchamd et al, 2008; Zimmerman et al, 2015; Torres et al, 2017), broncho-alveolar lavage (BAL) to 
estimate drug epithelial lining fluid (ELF) concentrations, remains the most widely used technique to 
assess “intra-pulmonary”drug concentrations 
ELF concentration is relevant to lumenally-targeted therapies such as antibiotics and is more 
accessible than tissue concentration.  Assessing free concentrations in lung tissue is difficult since 
the lung is a complex organ and concentrations may vary with the nature of the sample and the 
sampling site. In all methods, mechanical disruption of the tissue, processing time and dilution may 
release drug from depots, e.g. lysosomes or undissolved drug in airways. The latter is especially 
important for some of the more lipophilic drugs, where free drug in tissue may be a very small 
portion of total drug in lung.  Tissue sampling may be conducted both in animals and patients during 
surgery, but drug concentrations determined in whole tissue homogenates represent a mixture of 
intra and extracellular concentrations that are difficult to interpret, both for PK (characterization of 
the transport between plasma and lung) and PD purposes (prediction of drug efficacy).  
Considerations related to regional variation in drug concentrations are exemplified by the work of 
Boger et al (2016) in which overall target occupancy in lung (presumably an indirect measure of free 
tissue concentration in lung) was very similar to that observed in spleen following inhalation of a 
lipophilic drug, fluticasone propionate. The authors suggested that the observed clinical lung 
targeting of this inhaled corticosteroid could be explained by higher free drug concentrations, not in 
whole lung, but specifically in conducting airway tissue.  
Broncho-alveolar lavage (BAL), or micro-BAL, constitutes an interesting although not ideal means of 
measuring lung concentration.  As illustrated above, drug distribution within the lung is probably not 
homogenous and may differ between systemic administration and inhalation. BAL provides only an 
average concentration and must be corrected for dilution to get the more relevant ELF 
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concentration. This is usually done using measured urea concentration within BAL fluid and plasma 
which could add to the experimental error. Although BAL may be sampled relatively common in ICU 
patients with severe pulmonary infections, the number of BAL per individual is limited. Conducting 
BAL in other types of patients as well as in volunteers is seriously limited by ethical concerns. 
Furthermore, when powder formulations are used for inhalation, there may be some degree of 
uncertainty as to whether BAL solubilises drug that was undissolved in the lungs.  Yet overall ELF 
concentrations constitute probably the most utilised ‘lung concentrations’ for compartmental 
modelling (as described in Section 2.4).  
To conclude, a measure of free active drug at relevant target location is the ‘holy grail’ as it 
epitomises the true advantage of any topical treatment designed to provide an improved 
therapeutic ratio. Unfortunately, except for lumenally active inhaled antibiotics where ELF 
concentrations are accessible, free drug concentrations in lung are very difficult to assess 
experimentally. Hence, the usefulness of PBPK models to model free drug concentrations based on 
molecular physiochemical properties as well as experimental measures of lung tissue partitioning. 
However, the lack of clinical or preclinical data on pulmonary free tissue concentrations and its 
regional variation means that predictive models can only be indirectly validated with respect to 
predictions such as total tissue concentrations and total lung retention. 
2.6. Systemic PK models  
Although not the focus of this review, systemic PK models, preferably based on IV data, are required 
to convert a mechanistic model prediction of pulmonary and gastrointestinal absorption into a 
prediction of plasma concentration profiles. This is often the only validated prediction that can be 
made, thus access to accurate IV data and derived PK models is thus essential for any assessment of 
mechanistic absorption model robustness (Bäckman et al 2017). Unfortunately, published IV PK data 
is unavailable for many licensed inhaled medicines which limits model validation. When data is 
available, the application of compartmental analysis to plasma concentrations obtained after 
inhalation provides a semi-mechanistic understanding of the local absorption process. Expertise in 
systemic PK modelling is widespread and several user-friendly software’s are available. Plasma drug 
concentrations versus time profiles may be simulated within peripheral compartments, but this 
provides limited information since peripheral compartments correspond to virtual compartments 
with no anatomical meaning. To account for dissolution in lung an absorption compartment can be 
added, including for example the Weibull equation (Gaspar et al, 2016). If absorption kinetics 
determine the systemic drug concentration profile (‘flip-flop’ kinetics), plasma concentrations may 
reflect the absorption kinetics of a drug, especially if inhalation and IV PK data is obtained in parallel 
(Melin et al, 2017, Doan et al, 2013). Yet PBPK modelling constitutes a promising alternative and 
most PK studies of antibiotics in human lungs have been conducted with traditional compartmental 
analysis (Rodvold et al, 2011, Boisson et al, 2014).  
In summary, there are many examples where standard PK models applied to plasma concentration 
profiles have been helpful in understanding the extent and rate of pulmonary absorption, especially 
when plasma profiles for inhalation, oral and IV administration are obtained in parallel in same 
cohort (Melin et al, 2017). Systemic PK models based on IV data is also very useful as they provide 
one of the few means by which a mechanistic absorption model can be ‘validated’. Unfortunately, 
many inhaled drugs on market lack published IV data limiting the application of mechanistic models. 
Table 2.  Experimental techniques for quantitative evaluation of the disposition of drugs following 
aerosol deposition.   
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Parameter 
Potential 
Impact  Technique Status 
Supportive data 
required for 
modelling 
Comment 
Dissolution 
rate 
Dosing interval 
(pulmonary 
residence time), 
local irritation/ 
toxicity, systemic 
exposure (Cmax) 
Mechanistic 
computer models  
Models well established 
but lack of consensus on: 
Solubility media; ELF 
volumes and 
Concentration gradients; 
regional variability 
Solubility, pKa, Diffusion 
rate, particle size 
distribution, specific 
surface area, excipients, 
wettability, surface 
energy 
Criticality depends on 
kinetic competition with 
absorptive and non-
absorptive clearance 
 
Emerging commercial 
options: Unidose 
(Nanopharm), DissolveIT 
(ISAB). In vitro- in vivo 
predictability not firmly 
established 
In Vitro dissolution Variety of methods 
published with 
differences in aerosol 
capture, dissolution 
apparatus and medium.  
No consensus regarding 
to methodology, in vivo 
predictivity and media 
Solubility, local and 
regional surface density 
of doses, relevant PSD-
fraction 
Non-
Absorptive 
clearance 
Dosing interval 
(pulmonary 
residence time), 
pulmonary 
bioavailability 
(systemic AUC) 
Mechanistic MCC 
computer models 
Several models suggested 
by limited validation data 
available 
Total MCC, Regional MCC, 
Impact of disease 
MCC significantly impact 
luminal residence time of 
solids and mucin bound 
compounds Preclinical MCC 
models 
Measures total MCC or 
MCC in 1-2 airway 
generation. Very limited 
information on regional 
variability 
Patient inhalation flow 
profile to determine 
deposition pattern 
Metabolic 
degradation in 
lung homogenates 
and/or tissue 
slices 
Relatively well 
established techniques 
Chemical structure, 
reactive groups 
Normally not a significant 
contribution to non-
absorptive clearance in 
lung except for ante- and 
pro-drugs and 
macromolecules 
Absorptive 
Clearance 
Dose potency and 
targeting (ELF vs 
Tissue), Systemic 
exposure (Cmax) 
QSAR models Well established Physicochemical 
molecular properties 
related to experimental 
measures 
Predictive capability not 
proven 
In vitro Epithelial 
cell layers;  
 
Notably Calu-3, 
16HBE14o-well 
established models but 
methods not validated or 
standardized 
Drug concentrations in 
ELF 
Predictive capability not 
proven 
Ex-vivo/in vivo 
models 
 
IPL and PK well 
established  
Lung dose, deposition 
pattern 
Largely reflect AI region 
and not airways 
Local 
concentration 
Dosing interval 
(pulmonary 
residence time), 
Dose potency 
(local targeting) 
Therapeutic ratio 
Computational 
PBPK models 
Well established in PBPK Physicochemical 
properties, target affinity 
Not specific to lung 
tissue or relevant for 
mechanisms such as 
lysosomal trapping 
In vitro tissue 
partitioning 
(homogenates) 
Well established 
ultrafiltration and/or 
equilibrium dialysis 
 Difficult to separate out 
regions of interest. Not 
relevant for mechanisms 
such as lysosomal 
trapping (disruptive) 
In vitro tissue 
partitioning 
(whole tissue) 
Emerging: Recirculation 
IPL and lung tissue slices 
models in literature. No 
standardization.  
 Difficult to separate out 
regions of interest. More 
relevant for mechanisms 
such as lysosomal 
trapping (non-disruptive) 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
Total lung 
concentrations 
Lung tissue homogenates 
well established method 
but may not give an 
accurate estimation of 
free tissue levels at target 
due to physiological 
complexity of compound 
distribution 
 Interference from 
undissolved or trapped 
compound (disruptive) 
BAL Well established 
technique, interference 
from undissolved 
compound.  
 
 
 
Dilution, extent of solids Not easily accessible in 
man but very useful for 
accessing ELF 
concentrations for 
luminally active drugs 
such as antibiotics. 
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3. Mechanistic computer based models for simulating pulmonary and 
systemic exposure after inhalation  
 
3.1. Gastroplus ADRMTM  
GastroplusTM (GastroplusTM Nasal-Pulmonary Compartmental Absorption and Transit Model, 
SimulationsPlus Inc., Rochester, US) is currently the only commercially available mechanistic 
computer model that combines a physiological PBPK model with mechanistic models accounting for 
pulmonary deposition, dissolution, as well as absorptive and non-absorptive clearance (Figure 1). 
The program considers 3 distinct pulmonary regions (large and small conducting airways and 
alveolar interstitium, BB, bb and AI, respectively) and one extra thoracic compartment (ET), 
essentially based on the Weibel lung model (Weibel, 1963). Each region is sub divided into an airway 
liquid compartment and an epithelial/lung tissue compartment. For each sub-compartment the 
software allows the user to set relevant physiological parameters such as compartmental 
dimensions. 
 
Figure 1. Schematic outline of the GastroplusTM nasal and pulmonary absorption model. Dark blue = 
mechanistic model of initial aerosol deposition, dissolution, non-absorptive and absorptive clearance 
in pulmonary and GI lumen; Light amber = PBPK model describing pulmonary tissue free/bound drug 
concentration and diffusion into system; Dark amber = systemic disposition model. Airway regions 
defined in model: ET= Extra thoracic; BB= large airways (gen 0-8); bb=small airways (gen 9-16); 
AI=alveolar interstitial tissue (gen 17-23). 
The initial distribution of inhaled drug between these four compartments can be estimated based on 
a simple built-in IRCP-based 1-dimensional deposition model (IRCP, 1994). The deposition pattern 
can also be defined by the user, rendering the model compatible with any similar algebraic 
deposition models (for instance the ARLA and Mimetikos models described in section 2.1). However, 
the model cannot accommodate the distribution of surface drug concentration in different lung 
generations that can be obtained from a CFD-type model. Required input data for deposition 
modelling are listed in Table 1.   
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Following particle deposition, the software uses Noyes-Whitney principles to model dissolution 
mechanistically based on actual particle size distribution, solubility and diffusion rate (Table 2), thus 
providing in theory an accurate reflection of real dissolution disparities imposed by differences in the 
product, e.g. changes in APSD according to variations in manufacturing processes. However, the 
software does not allow for the direct use of real dissolution profiles or data derived from such 
profiles.  
Non-absorptive clearance is described by a first order mucociliary transport model simulating the 
upwards transport of drug in lumen into the extra-thoracic compartment and from there into the 
gastrointestinal compartments (O’Riordan et al, 1992).   
Absorptive clearance of dissolved drug from airway liquid into lung tissue is assumed to be limited by 
either passive permeability limited diffusion or by active transport processes as regulated by a 
compartment specific permeability function. The main substance specific variable here is the 
alveolar interstitial permeability. The software estimates this values based on the molecular weight, 
(but it can also be entered by the user) and then scales this value to other airway regions based on 
epithelial thickness. However, regional airway permeability is not easily accessible making this 
variable subject to some uncertainty (Table 2).  
The inclusion of two kinetically competing process of absorptive and non-absorptive clearance, in 
combination with a mechanistic dissolution model, allow the user to simulate the impact of 
variations in deposition pattern and dissolution rate on total pulmonary bioavailability and rate of 
absorption (se e.g. Bäckman et al, 2017, Bäckman and Olsson, 2016, Olsson and Bäckman 2014).   
Absorption from lung tissue into the systemic circulation is assumed to be a diffusion limited process 
and is as such governed by the blood flow through the tissue and the blood tissue partitioning 
function. The latter is derived from standard blood plasma partitioning and from tissue plasma 
partitioning, parameters that can be measured experimentally (Table 2) or calculated from 
physicochemical data using standard PBPK type approaches. More complex tissue interactions, such 
as sequestration into lysosomes reported to be a main contributor to the retention of di-bases in 
lung, cannot be simulated. 
3.2. PK-SIM™ and SimCyp SimulatorTM 
Although Gastroplus is the only commercially available software to incorporate a mechanistic model 
of deposition, dissolution, non-absorptive clearance and absorptive clearance, non-mechanistic 
PBPK models are available.  The SimCyp SimulatorTM 
(https://www.certara.com/software/physiologically-based-pharmacokinetic-modeling-and-
simulation/simcyp-simulator/absorption/) and PK-SIM™ (Computational Systems Biology: Bayer AG, 
http://www.systems-biology.com/products/PK-Sim.html) allow the user to define pulmonary and 
gastrointestinal (GI) absorption compartments and model PK following pulmonary administration.   
For example, Stass et al, (2008, 2013) used PK-SIM to deconvolute PK data obtained in healthy 
volunteers after inhalation of ciprofloxacin, a locally acting antibiotic, to obtain the relative 
contribution of oral, tracheobronchial (BB and bb) and alveolar interstitial (AI) deposited drug to the 
total systemic exposure. The authors did not mechanistically model local absorptive and non-
absorptive clearance processes but rather assumed the AI dose to behave as an IV dose and the Bb 
dose to behave as a delayed oral dose and then used PK-Sim to fit the systemic PK profiles based on 
these assumptions.  
Gauhua et al., (2015) used a multicompartment lung model embedded in the SimCyp PBPK-model to 
study the local (pulmonary) and systemic pharmacokinetics of anti-tuberculosis (TB) drugs.  
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Although, the model studied lung exposure following systemic administration of drugs, it is relevant 
to lung targeting owing to the realistic physiology of the lungs taken into consideration. Regional 
differences in gas exchange, blood perfusion and transporter expressions were modelled to predict 
ELF:plasma concentration ratio of administered anti-tuberculosis drugs with reasonable 
approximation to observed clinical data. Alteration of ELF pH or inclusion of transporter activity 
suggested significant potential for altering the ELF:plasma concentration ratio of administered drugs. 
The model provided a framework to optimize dosage regimes in tuberculosis patients to achieve 
maximum therapeutic efficacy. 
These models are of obvious value as PBPK models for predictions of preclinical and early clinical 
exposures but they reduce dissolution and epithelial permeation into non -mechanistic 1st order 
processes. This limits the ability of these models to account for real product performance variables 
and differences between lung regions with respect to the nature of, and balance between, 
absorptive and non-absorptive clearance.  
 
 
Figure 2. Schematic outline of pulmonary absorption in SimCyp SimulatorTM. Dark blue = non- 
mechanistic model of initial aerosol deposition including a first-order model of absorptive clearance 
in pulmonary and GI lumen; Light amber = PBPK model describing pulmonary tissue free/bound drug 
concentration and diffusion into system; Dark amber = systemic disposition model. Airway regions 
defined in model: ET= Extra thoracic; Lung = (gen 0-23). 
 
3.3. In-house industry models  
In addition to the commercially available software programmes, a variety of bespoke mechanistic 
pulmonary absorption models have also been devised.  Although mostly developed and applied to 
guide the commercial development of inhaled medicines, these have been published to various 
extents and/or presented at scientific workshops and symposia. 
In a recent paper, Boger et al. (2016) predicted the fate of a poorly soluble inhaled drug, fluticasone 
propionate, in rats. A combined framework of drug and formulation-specific properties along with 
system-specific inputs were explored using a computer based PBPK model to predict lung selectivity 
(ratio of local to systemic target occupancy). The time course of glucocorticoid receptor occupancy 
in lungs was measured in vivo following inhalation and intravenous administration of fluticasone 
propionate. Mechanistic modelling simulations were found to be predictive of the pharmacokinetics 
and receptor occupancy of FP following intravenous and nose-only inhalation delivery. Key findings 
of the research were that it is difficult to achieve lung selectivity in well perfused parts of the lungs 
and that slow drug-receptor dissociation can be the molecule property critical for the lung 
selectivity.  
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PulmoSim™, Pfizers in-house PBPK model, has unfortunately not been fully described in a peer 
reviewed journal.  However, the model has been presented at meetings. For instance, Jones 
described the development and application of PulmoSim™ at a society of medicines Research 
Symposium (Collingwood et al, 2012). PulmoSim was claimed to incorporate mechanistic descriptors 
of  drug dissolution, permeation, lung tissue distribution, as well as a systemic distribution and 
dissipation model. The model was claimed to have been validated  against preclinical data on 
compounds covering a wide physico-chemical space. Jones concluded that the model was useful in 
predicting human systemic PK but also that validation of local pulmonary drug concentrations were 
challenging.  
Recently, Merck developed an in silico mechanistic model to enable predictions of local pulmonary 
tissue concentrations during respiratory drug development (Caniga et al, 2016, Cabal et al, 2016). 
The model integrates a typical lung generation deposition model, dissolution, MCC (large and small 
airways) and an absorption module with a PD module and a PBPK module. Model predictions have 
been validated against systemic PK data in rat and humans following local delivery of momethasone 
furoate, budesonide, salbutamol, and formoterol. The authors concluded that the model provided 
valuable information regarding lung targeting (pulmonary vs systemic concentration ratio) and how 
this could be optimized. 
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4. Knowledge gaps and research priorities to support model 
development 
 
Historically, novel inhaled drugs, as well as generic equivalents, were developed mainly using in vitro 
and in vivo experimental models. As described in preceding sections, significant efforts are now 
being made to predict or understand key processes that determine pulmonary exposure to inhaled 
drugs.  For example, tissue retention and passive permeability of drugs have been projected using 
QSAR and PB/PK modelling (Tronde et al 2003a, 2003b; Boger at al 2016)). However, key questions 
facing the developer of a new drug remain indeterminate, either because of a lack of adequate 
experimental methods or because the answer depends on how product properties (such as 
deposition and dissolution) interact with API behaviour conferred by molecular properties (such as 
permeability, tissue affinity and receptor affinity) and local physiology (including MCC, metabolism, 
epithelial permeability and target location). Typical questions of this nature may be: 
 How can solubility, tissue affinity and potency be best balanced to provide dose potency and 
duration of effect? 
 Does target location impose different requirements of the API and the deposition pattern of 
the aerosol? 
 Can we translate data on non- absorptive clearance from animal models to humans? 
 How does smoking or disease type and severity modify aerosol deposition and subsequent 
pulmonary drug clearance? 
Computer based mechanistic modelling provide an opportunity to explore questions like those 
above by a combination of: (i) understanding the key processes determining local and systemic 
exposure; (ii) having access to biorelevant experimental data characterizing these processes; and (iii) 
integrating the experimental data and mechanistic process understanding using computer based 
mechanistic models. This is obviously recognised by the pharmaceutical industry, as exemplified by 
recent presentations/publications from Merck (Caniga et al 2016), Pfizer (Collingwood et al, 2012) 
Bayer (Stass et al 2013) and AstraZeneca (Bäckman et al, 2017, Boger et al 2016)). Unfortunately, as 
this review identifies, significant gaps in understanding drug uptake by the lungs and available 
methods/models to study this quantitatively are barriers to a more widespread and successful 
utilization of the mechanistic modelling approach (Table 3).   
Table 3.  Identified gaps and potential questions to be addressed in future research 
Gap Clinical impact Questions and topics for future research 
Validated 
predictions of 
lung deposition 
pattern 
Efficacious dose 
Systemic 
exposure 
Several publications have indicated the necessity to understand aerosol deposition pattern, and how this 
relates to specific products and patients. Currently, pulmonary deposition patterns beyond large airways 
are only accessible through 1-dimensional computer models based on inhalation manoeuvre, standard 
Weibel-type lung models and APSD measure. Outstanding questions are: 
 Can a standardized method for biorelevant pulmonary deposition modelling be established? 
 Can relevant experimental in vivo validation techniques be identified? 
Models of 
dissolution in 
lung 
Duration, 
Irritation 
Dissolution in lungs, as well as its variation between pulmonary regions, is a key predictor of rate and 
extent of absorption for poorly soluble drugs. Important questions are:  
 For which compounds is dissolution rate limiting and in which lung regions (input to a pulmonary 
biopharmaceutical classification system?) 
 Can a pharmacopoeial standard for biorelevant in vitro test methods be established?  
 How can in vitro dissolution results be linked to in vivo impact? What is the role of computer 
models? Does regional variation need to be considered? 
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Variation in 
mucociliary 
clearance rate 
Bioavailability, 
Duration 
MCC is the predominant non-absorptive clearance process for powder aerosols of poorly soluble inhaled 
small molecules and as such it influences both bioavailability and duration of therapeutic effect in humans.  
 Can regional and disease driven variations in MCC be measured and modelled? 
 How should a biorelevant mechanistic model of MCC be designed – what is the relevance of first 
order models? 
Regional 
variation in 
epithelial 
permeability 
Bioavailability, 
Duration 
For very hydrophilic and macromolecular drugs, permeability may be the rate limiting absorption step.  It is 
possible that active transport processes influence bioavailability in airways. Poorly soluble drugs may also 
show permeability limitations in larger airways due to competition for retention in lung tissue. 
 Can experimental models for assessing regional variability in transcellular epithelial permeability 
be identified and results used to establish more relevant mechanistic models?  Is permeability 
affected by disease, smoking, etc.. 
 What is the impact of transporters (especially in airway regions) – can we measure and model 
this? 
Pulmonary 
concentrations 
Potency and 
duration of effect 
A direct or indirect measure of free drug concentrations (and its regional variation) in lung is challenging 
using existing methods (except for measuring ELF) but critical for the validation of any computer based 
model aiming to support compound development.   
 Can a usable method be established for direct or indirect measurements of free drug 
concentrations? Can developments in techniques such as positron emission tomography provide 
measurement techniques?  
Validation of in 
silico models 
Potency and 
duration of effect 
Currently, only one commercially available computer model combines a mechanistic approach to 
predictions of deposition, dissolution, absorptive and non-absorptive clearance with a PBPK model, and 
literature data validating this model against experimental observations is scarce. Several models with 
these features have been published or presented at scientific meetings, but so far are either not publicly 
available or have no human data validation, or both. 
 Can a wider selection of mechanistic models be made available with (preferably) access to key 
model assumptions to increase transparency? 
 How can in silico models be validated, against each other and against human clinical data? 
Publications combining clinical data, in vitro product performance data and in silico simulations 
are required to demonstrate robustness of approach.  
 
Identified gaps and barriers to greater and better use of modelling approaches range from the need 
for accurate and validated prediction of lung deposition pattern to the accurate assessment of drug 
concentration in the lungs (Table 3). A concerted effort to address these deficiencies could 
significantly improve the success rate in bringing novel inhaled drugs to the clinic – thus bringing 
medical value.  
A better understanding of key drivers of local and systemic exposure, and an improved ability to 
characterize and model these processes could also have an impact on the regulatory landscape. As 
an example, generic equivalents as well as post approval changes for inhaled proprietary medicines 
face an elevated regulatory hurdle compared to oral drugs. This is mainly a result of inadequate (or 
not standardized) means to predict and assess the potential combined impact of API properties and 
product properties on clinical safety and efficacy. Today, this prohibits for instance the use of a 
classification system such as the biopharmaceutical classification system which currently guides drug 
development and provides options for regulatory relief for oral medicine licensing (Hastedt et al, 
2016). 
Questions related to modelling include, what will be required for modelling to be accepted to 
support regulatory submissions for original or generic products?  Is modelling used for other 
products for regulatory purposes?  Would development of models and their utilisation be helped by 
greater recognition of the benefits by industry and appropriate expertise in academia and the 
pharmaceutical research community, plus greater communication and liaison between 
experimentalists and modellers?  At present, the number of different models, their assumptions and 
the lack of transparency regarding their underlying assumptions present a problem for peer review, 
accessibility and acceptance. 
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To extend the scope of current models, factors identified as important by empirical modelling, e.g. 
disease or smoking could be incorporated and scenarios where in vitro and in vivo data are at 
variance (Borghardt et al 2016a; Borghardt et al 2016b; Bartels et al 2013), can be investigated to 
improve modelling and understanding of inhaled drug delivery.  The level of detail that is necessary 
in PBPK models, such as the number of lung regions modelled and the refinement of region-specific 
physiological parameters, e.g. epithelial permeability, metabolism, solubility in lung fluid, provides 
another topic for investigation.  Finally, to realise the full potential of modelling, the linking of lung 
exposure to drug action is required in the form of mechanism-based pharmacokinetic-
pharmacodynamic modelling.  Such ‘systems pharmacology’ approaches are beyond the scope of 
the current article, but provide the key link between drug exposure and drug response, and even the 
relationship between drug response and disease progression [e.g. Danhof et al 2008]. 
In conclusion, successful application of transparent mechanistic in silico models informed by robust 
experimental data could benefit discovery of new API’s and development of novel inhaled 
medicines. A better understanding of the science in this area could also impact on the regulatory 
landscape and potentially provide some science-based regulatory relief facilitating approval of 
generic equivalents, as well as post approval changes. Beyond the pharmaceutical sector, such 
models may also prove valuable for risk assessment for environmental air pollutants, occupational 
inhalation exposures such as crop spraying or aerosol cleaning/healthcare products, and biodefence 
against airborne agents. Improvements in experimental methods as well as an increased availability 
(commercial or otherwise) of in silico methods as suggested here (Table 3) are likely to benefit such 
a development. The latter could also result in more wide spread use within both industry and 
academia, and hopefully, more published scientific studies.  Currently, too few examples are 
available in literature that combine a transparent presentation of key in vitro product characteristics, 
clinical results and mechanistic in silico model simulations to provide a sufficient data base for 
validation and improvement of existing models.  
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